as nyse ebs founded 1998 headquarters gaithersburg maryland key people list fuad el hibri executive chairman of the board of directors daniel j. abdun nabi president and chief executive officer revenue us 445 500 million 2014 operating income us 42.8 million 2014 profit us 53 55 million 2014 website official website footnotes references 1 2 3 4 5 6 7 8 emergent biosolutions is a multinational specialty biopharmaceutical company headquartered in gaithersburg maryland . 9 it develops vaccines and antibody therapeutics for infectious diseases oncology and autoimmune disorders and provides medical devices for biodefense purposes . among the company s notable products is biothrax anthrax vaccine adsorbed the only anthrax vaccine licensed by the u.s. food and drug administration fda . the company also manufactures pharmaceuticals for adults and children with acute blood disorders people undergoing certain liver transplants palliative care for chemo or radiation therapy patients hemophilia b and a varicella chickenpox vaccine for high risk patients . the company has two divisions a biodefense division for medical countermeasures and a biosciences division to treat infectious disease autoimmune diseases and cancer . 10 fuad el hibri the founder of the company and former ceo 11 led the company since its founding as bioport inc. 10 12 until his retirement on april 1 2012 . 13 14 el hibri continues to serve as the executive chairman of emergent biosolutions board of directors . 15 contents 1 biothrax 2 company history 2.1 founding 2.2 2001 anthrax attacks 2.3 emergent biosolutions and acquisitions 2.4 initial public offering ipo 2.5 centers for innovation in advanced development and manufacturing 2.6 zika virus vaccine 3 daniel j. abdun nabi ceo 4 financial information 4.1 2014 2015 activity and financial figures 5 r & d and manufacturing operations 6 corporate social responsibility 7 public affairs 8 see also 9 references 10 notes 11 external links biothrax edit further information anthrax vaccine anthrax vaccine adsorbed according to the u.s. national library of medicine biothrax was first made available in 1970 . 16 biothrax anthrax vaccine adsorbed a vaccine licensed by the u.s. food and drug administration . 17 following a study by scientists from the centers for disease control and prevention 18 on december 19 2008 emergent received final fda licensing for use of biothrax five doses for intramuscular injection . 19 later in 2009 emergent received approval from the fda to extend the shelf life of its anthrax vaccine from three to four years . biothrax was approved for distribution in the united states . 20 not in citation given biothrax has received marketing approval in india singapore and germany . 21 22 23 the fda gave biothrax an orphan drug designation in april 2014 . 24 the fda gives that status to drugs that are used to treat rare diseases . 24 biothrax is the only anthrax vaccine licensed by the fda . 24 as of april 2014 emergent has sold over 66 million doses of biothrax to the u.s. government . 25 three million u.s. military personnel have received the biothrax vaccine . 25 the main buyer of biothrax is the u.s. centers for disease control and prevention cdc . 26 the cdc buys biothrax for the strategic national stockpile sns . 26 the government uses the sns to protect the public in the event of a national emergency like a terrorist attack . 26 emergent submitted an application to the fda for use of a large facility in lansing michigan to produce biothrax . on june 21 2016 emergent announced that it had moved a step forward in the process the fda completed the pre approval phase of its inspection . 27 company history edit acquisition history 2003 2003 antex biologics inc. 28 2005 2005 microscience ltd. 29 2006 2006 vivacs gmbh 30 2008 2008 a group of anthrax monoclonal antibodies from avanir pharmaceuticals 31 2008 2008 anthrax vaccine program patents and processes from vaxgen 32 33 2010 2010 trubion pharmaceuticals 34 2013 2013 healthcare protective products division of bracco diagnostics inc. which includes rsdl decontamination lotion 35 36 2014 2014 cangene corporation 37 38 founding edit emergent biosolutions was founded on september 5 1998 under the name bioport . at the time the michigan department of public health though its michigan biologics products institute owned an anthrax vaccine manufacturing facility in lansing michigan . bioport purchased the facility and the rights to manufacture the vaccine for the u.s. military . 39 40 2001 anthrax attacks edit after the september 11 2001 and the anthrax attacks that followed emergent worked with the u.s. government to supply anthrax countermeasures . 41 emergent biosolutions and acquisitions edit bioport was renamed emergent biosolutions in 2004 . 42 between 2003 and 2014 emergent acquired several companies and product lines . see acquisition history box to the right . initial public offering ipo edit emergent became a publicly traded company in 2006 with its stock trading on the new york stock exchange under the symbol ebs . 41 centers for innovation in advanced development and manufacturing edit in june 2012 emergent along with novartis and the texas a & m university system was selected by the u.s. department of health and human services as one of the three centers for innovation in advanced development and manufacturing . the public private partnership granted emergent 163 million over eight years to assist in the development of countermeasures for health nuclear and radiological epidemics . 43 the point of the sites is to produce medical countermeasures in the event of a national pandemic . 44 emergent s site is located in maryland . the company expects the site to be operational by the year 2020 . 44 zika virus vaccine edit on june 27 2016 the federal government s biomedical advanced research and development authority barda contracted with emergent biosolutions to develop a vaccine for the zika virus . the contract is spread out over 30 months and is worth around 22 million . 45 30 the vaccine could reach stage one clinical trials by early 2017 . 46 as of the end of june 2016 60 countries and territories had reported transmission of the zika virus from mosquitoes . 45 emergent could become the first company to develop a vaccine for the virus . 30 daniel j. abdun nabi ceo edit the current president and ceo of emergent biosolutions is daniel j. abdun nabi . he has held the position since april 1 2012 . 47 prior to that he was the president and chief operating officer . he holds an m.l.t. from georgetown university j.d. from the university of san diego and b.a. from the university of massachusetts amherst . 48 in addition to running emergent abdun nabi speaks publicly on matters related to national security . for example on april 1 2015 he spoke as a panelist before the hudson institute think tank about how to prepare and respond to threats from biological and chemical weapons . the event was part of the blue ribbon study panel on biodefense a group of experts that analyzed the united states defense capabilities against biological threats . 49 in 2015 abdun nabi organized a visit by former florida governor jeb bush to emergent s lansing facility to speak to employees about ways the government and companies such as emergent could work with each other to help defend the u.s. against terrorist attacks . 50 abdun nabi sits on the board of directors at biohealth innovation a public private partnership that helps bring bio health products to the marketplace . 51 abdun nabi serves on the universities at shady grove board of advisors . abdun nabi and john kenyon a fellow adviser published an op ed in the washington business journal on july 14 2016 . in the article they discuss the issue of education deserts around the united states . they wrote high tech businesses are experiencing a surge in stem related hiring needs and that over the next quarter century 25 percent of nationwide job growth is projected to be in health healthcare delivery and biosciences fields . 52 financial information edit forbes recognized emergent as the top performing company in the state of maryland for the 2015 2016 fiscal year . forbes tracked the return of every public company between from june 8 2015 to june 8 2016 . emergent had a total return during that time period of 38.2 percent . in 2015 emergent had revenue of 522 million . 53 2014 2015 activity and financial figures edit according to zacks emergent s acquisition of cangene made both of emergent s divisions biosciences and biodefense stronger . in addition to the cangene acquisition emergent and the german human antibody developer morphysys ag in 2014 began collaborating on a prostate cancer drug called es414 . as of january 2015 the drug is in the pre clinical stage . 54 in early january 2015 emergent publicly released its preliminary financial totals for the 2014 year . the company saw an increase in revenue gaap net income a and adjusted net income . revenue amounted to between 445 450 million which is 43 % higher than revenue earned in 2013 . gaap net income was between 36 and 38 million a 19 % increase . adjusted net income increased by 49 percent to between 53 and 55 million . 55 also in january the company gave what is known as guidance an accounting term meaning a company tells the public what it expects to earn in the future 56 for 2015 . emergent expects 90 105 million in sales in the first three months of 2015 ; and between 510 540 million for the full year . 54 emergent sold more biothrax in 2014 than in the previous year biothrax sales amounted to approximately 246 million . according to company statements emergent believes that the growth in biothrax sales along with stronger sales of other products from its biodefense division will drive growth in 2015 . 55 the motley fool an investment information company characterized in its yahoo finance profile as the king of personal investing tips 57 believes that emergent s drug to treat hemophilia b called ixinity will also drive growth in 2015 . as of january 21 2015 the fda was reviewing emergent s application for ixinity approval . 58 key financial figures current as of january 21 2015 are listed in the table 59 measure header market capitalization 1 040 000 000 enterprise value 1 070 000 000 profit margin 5.46 % operating margin 12.19 % cash on hand 242 250 000 debt 251 000 000 debt equity ratio 43.92 r & d and manufacturing operations edit main article anthrax vaccine adsorbed in addition to the anthrax vaccine emergent biosolutions develops and manufactures vaccines and therapeutics for the prevention or treatment of several diseases . 60 one of emergent s medical countermeasure products is a lotion that clears and neutralizes chemical warfare agents . the product is called reactive skin decontamination lotion kit rsdl . 61 rsdl removes or neutralizes agents within two minutes . the product is used in over 20 countries around the world . 62 rsdl is made of the chemicals dekon 139 2 3 butanedione monoxime dam . according to the chemical hazards emergency medical management office within the united states department of health and human services rsdl is used as a medical device for the decontamination of skin exposed to chemical warfare agents such as sulfur mustard vx vr and certain biological toxins . the body s first line of defense against chemical agents is the skin . when a chemical agent is able to penetrate the skin additional medical countermeasures are needed such as rsdl . 63 the following table shows the company s marketed products as of may 2014 2 64 65 name disease therapeutic area treats stage type anthrasil anthrax immune globulin intravenous anthrax inhalational anthrax marketed therapeutic 66 bat botulism antitoxin heptavalent a b c d e f